Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20518637 | 1.00 | KDM4E (0.45) | KDM4ECYP26A1TBXA2RTBXAS1CYP17A1 | |
| Bromide SCHEMBL28354965 | 0.98 | KDM4E (0.44) | KDM4ECYP26A1TBXA2RTBXAS1CYP17A1 | |
| Hydrochloric Acid SCHEMBL27966647 | 0.98 | KDM4E (0.44) | KDM4ECYP26A1TBXA2RTBXAS1CYP17A1 | |
| Sulfuric Acid SCHEMBL28494274 | 0.93 | KDM4E (0.41) | KDM4ECYP26A1TBXA2RTBXAS1CYP17A1 | |
| SCHEMBL28177904 | 0.83 | KDM4E (0.42) | KDM4ECYP26A1TBXA2RCYP17A1CYP19A1 | |
| SCHEMBL17484629 | 0.83 | KDM4E (0.42) | KDM4ECYP26A1TBXA2RCYP17A1CYP19A1 | |
| SCHEMBL4171040 | 0.82 | KDM4E (0.41) | KDM4ECYP26A1TBXA2RCYP17A1CYP19A1 | |
| SCHEMBL27673215 | 0.82 | KDM4E (0.41) | KDM4ECYP26A1TBXA2RCYP17A1CYP19A1 | |
| Bicarbonate SCHEMBL28505567 | 0.81 | KDM4E (0.46) | KDM4ECYP26A1TBXAS1CYP17A1CYP19A1 | |
| SCHEMBL27968394 | 0.80 | CYP26A1 (0.45) | KDM4ECYP26A1TBXAS1CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104662004-B | Novel rebamipide prodrug, method for producing same, and usage thereof | 三进制药株式会社 | 2017-04-19 | — | — | CN | claimed |
| CN-102690291-B | Imidazole ionic liquid supported chiral phosphine ligands and preparation method thereof | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2014-07-30 | — | — | CN | claimed |
| CN-101678011-A | Spiro-indolinone compounds | MERCK & CO INC | 2010-03-24 | — | — | CN | claimed |
| CN-119522299-A | Use of a composition comprising a polyaminoamide-type compound for copper nano twin electrodeposition | 巴斯夫欧洲公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-118043502-A | Composition for copper electrodeposition comprising a polyaminoamide leveling agent | 巴斯夫欧洲公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2021252859-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3820474-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | Nikang Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-107353431-B | Aluminum-plastic composite packaging material separating agent based on ionic liquid and separating method thereof | 陕西科技大学 | 2020-11-20 | — | — | CN | disclosed |
| US-7666851-B1 | Three ring fused analogs of isoguanosine | BENNER STEVEN ALBERT | 2010-02-23 | — | — | US | disclosed |
| WO-2008099165-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | disclosed |
| US-7384731-B2 | Method for forming color image and silver halide color photosensitive material used for the same | FUJIFILM CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7250456-B2 | Composition and its use for imparting water repellency to leather or furskins, textiles and other fibrous materials | TFL LEDERTECHNIK GMBH (DE) | 2007-07-31 | — | — | US | disclosed |
| US-20050148702-A1 | Composition and its use for imparting water repellency to leather or furskins, textiles and other fibrous materials | TFL LEDERTECHNIK GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
| EP-1470258-A1 | COMPOSITION AND ITS USE FOR IMPARTING WATER REPELLENCY TO LEATHER OR FURSKINS, TEXTILES AND OTHER FIBROUS MATERIALS | TFL Ledertechnik GmbH (DE) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003064707-A1 | COMPOSITIONS AND ITS USE FOR IMPARTING WATER REPELLENCY TO LEATHER OR FURSKINS, TEXTILES AND OTHER FIBROUS MATERIALS | TFL LEDERTECHNIK GMBH (DE) | 2003-08-07 | — | — | WO | disclosed |
| US-5703241-A | TREATING CANCER | MERCK & CO., INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5387585-A | Treating epilepsy, anxiety, sleep disorders, schizophrnia, senile dementia | HOFFMANN-LA ROCHE INC. (US) | 1995-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KDM4E 3398/4885CYP26A1 1323/4885TBXA2R 122/4885 |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | KDM4E 4564/4885CYP26A1 1444/4885TBXA2R 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.